Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai, shared a post on LinkedIn:
“ESMO2025 | Lung Cancer – What’s New?
From next-gen KRAS inhibitors to DLL3 T-cell engagers and cutting-edge ADCs with intracranial activity, the momentum in thoracic oncology is unmistakable.
Highlights include:
- EGFR × HER3 bispecific ADCs
- DLL3-targeted T-cell engagers (Obrixtamig, Gocatamig)
- Ifinatamab deruxtecan in SCLC brain metastases
- Novel IO combos – Serplulimab, EIK1001 (TLR7/8)
- New EGFR and KRAS inhibitors (Firmonertinib, Olomorasib, Zipalertinib)
- KEYMAKER-U01 umbrella strategy
Each of these represents real innovation: moving from “better chemo” to molecularly precise, CNS-active, immune-potentiating drugs.
Infographic below captures the 10 new molecules in lung cancer set to make waves at ESMO 2025.”
More from Amol Akhmade on OncoDaily.